BMO Capital Markets restated their outperform rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report released on Friday. They currently have a $195.00 price objective on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Deutsche Bank AG reiterated a buy rating and set a $158.00 target price (up previously from $155.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. Leerink Swann reiterated a buy rating and set a $202.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. Goldman Sachs Group Inc. reiterated a buy rating and set a $195.00 target price (down previously from $196.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. Barclays PLC reiterated a buy rating and set a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 10th. Finally, Mizuho increased their target price on Jazz Pharmaceuticals PLC from $193.00 to $195.00 and gave the stock a buy rating in a report on Tuesday, July 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $185.00.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 1.47% during trading on Friday, hitting $124.62. The company had a trading volume of 130,204 shares. The stock has a 50-day moving average of $125.26 and a 200-day moving average of $139.52. Jazz Pharmaceuticals PLC has a one year low of $108.50 and a one year high of $160.00. The stock has a market capitalization of $7.54 billion, a PE ratio of 21.91 and a beta of 0.96.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.80 by $0.17. The firm had revenue of $381 million for the quarter, compared to the consensus estimate of $376.40 million. Jazz Pharmaceuticals PLC had a return on equity of 28.39% and a net margin of 25.46%. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter last year, the company posted $2.41 EPS. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post $9.97 EPS for the current year.

In related news, CMO Karen L. Smith purchased 580 shares of the firm’s stock in a transaction dated Wednesday, July 13th. The shares were purchased at an average price of $143.63 per share, with a total value of $83,305.40. Following the acquisition, the chief marketing officer now directly owns 13,574 shares of the company’s stock, valued at $1,949,633.62. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $126.17, for a total transaction of $25,234.00. Following the completion of the transaction, the senior vice president now directly owns 17,325 shares in the company, valued at approximately $2,185,895.25. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Loomis Sayles & Co. L P raised its position in shares of Jazz Pharmaceuticals PLC by 0.4% in the first quarter. Loomis Sayles & Co. L P now owns 13,839 shares of the specialty pharmaceutical company’s stock worth $1,807,000 after buying an additional 50 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Jazz Pharmaceuticals PLC by 9.3% in the first quarter. UBS Asset Management Americas Inc. now owns 145,259 shares of the specialty pharmaceutical company’s stock worth $18,963,000 after buying an additional 12,328 shares during the last quarter. State Street Corp raised its position in shares of Jazz Pharmaceuticals PLC by 7.7% in the first quarter. State Street Corp now owns 1,333,938 shares of the specialty pharmaceutical company’s stock worth $174,128,000 after buying an additional 95,849 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Jazz Pharmaceuticals PLC by 5.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,265 shares of the specialty pharmaceutical company’s stock worth $296,000 after buying an additional 107 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Jazz Pharmaceuticals PLC by 1,120.5% in the first quarter. Canada Pension Plan Investment Board now owns 13,718 shares of the specialty pharmaceutical company’s stock worth $1,791,000 after buying an additional 12,594 shares during the last quarter. 88.25% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.